QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

(SP-4-2)-diamminedichloroplatinum(II)

5-fluoro-2,4 (1H,3H)-pyrimidinedione

2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine

Ad5 \[E1-, E2b-\]-Brachyury vaccine

Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine

RAS yeast vaccine

Brachyury yeast vaccine

INNO-206

Fully human anti-PD-L1 IgG1 lambda monoclonal antibody

recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]

NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)

Docetaxel

carboplatin